Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 250,000 shares, an increase of 189.4% from the December 31st total of 86,400 shares. Based on an average daily volume of 3,070,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.8% of the company’s stock are sold short.
Bio-Path Stock Performance
Shares of NASDAQ BPTH traded up $0.03 during mid-day trading on Thursday, reaching $0.82. The company had a trading volume of 71,476 shares, compared to its average volume of 176,388. Bio-Path has a 1-year low of $0.59 and a 1-year high of $9.99. The company has a 50-day moving average price of $0.89 and a two-hundred day moving average price of $1.08.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on Bio-Path in a report on Wednesday. They issued a “sell” rating for the company.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- What Makes a Stock a Good Dividend Stock?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- The Basics of Support and Resistance
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- How to buy stock: A step-by-step guide for beginners
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
